FDA approves new type of therapy to treat advanced urothelial cancer
FDA granted accelerated approval to Padcev, indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer
Related Articles
Vivek Subbiah: ASCO 2025 Annual meeting is shaping up to be incredible – OncoDaily
Vivek Subbiah: ASCO 2025 Annual meeting is shaping up to be incredible / American Society of Clinical Oncology, ASCO, ASCO 2025, cancer, OncoDaily, Oncology,
Urinary DNA Methylation Test for Bladder Cancer Diagnosis
This prospective multicenter study including individuals with hematuria evaluates the performance of a urinary DNA methylation test in identifying patients with high-grade or invasive bladder…
Intracranial Outcomes in Melanoma Brain Metastases After Anti–PD-1 Therapy
This cohort study examines the response and survival rates associated with ipilimumab-nivolumab therapy in patients with progressive melanoma brain metastases after anti–programmed cell death 1…
5 articles suggested by Vivek Subbiah – OncoDaily
5 articles suggested by Vivek Subbiah / A. Ari Hakimi, A. Ducassou, A. Italiano, A. Michot, Abhinav Pandey, Abraham S. Singh, Aby Abraham, Aleksandra
The science behind the first pig-organ transplant trial in humans
Nature – The small trial will help to establish whether kidneys from genetically modified pigs can be transplanted into people safely and effectively.
Results of a phase Ib study of olaparib with concomitant radiotherapy in soft-tissue sarcoma: a French sarcoma group study
Radiotherapy is essential for locoregional control in resectable soft-tissue sarcoma (STS) and remains a key strategy for unresectable STS. PARP inhibitors, such as olaparib, may…
Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data
Nature Medicine – Using multiple datasets from real-world evidence and completed trials, a machine learning model using routine blood and clinical data is shown to…
Predisposition Footprints in the Somatic Genome of Wilms Tumors
Abstract. Approximately 10% of children with cancer harbor a mutation in a predisposition gene. In children with the kidney cancer Wilms tumor, the prevalence is…
Insights into the future of first-line advanced hepatocellular carcinoma treatment
Atezolizumab plus bevacizumab is the standard of care for patients with advanced hepatocellular carcinoma. Building on the impressive results of IMBrave150,1 the phase 1b–2 MORPHEUS-Liver…
Second Primary Cancer After Chimeric Antigen Receptor–T-Cell Therapy
This review examines the incidence of second primary cancers after treatment with chimeric antigen receptor T cells in patients with hematologic cancers.